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 Abstract 
 
TCDD (2,3,7,8-TetraChloroDibenzoDioxin), a highly persistent environmental pollutant 
and a human carcinogen, is the ligand with the highest affinity for the Aryl 
Hydrocarbon Receptor (AhR) that induces via the AhR, xenobiotic metabolizing enzyme 
genes as well as several other genes.  This pollutant elicits a variety of systemic toxic 
effects, which include cancer promotion and diverse cellular alterations that modify cell 
cycle progression and cell proliferation. Large-scale studies have shown that the 
expression of Son of Sevenless 1 (SOS1), the main mediator of Ras activation, is one of 
the targets of dioxin in human cultured cells. In this study, we investigated the 
regulation of the previously uncharacterized SOS1 gene promoter by the AhR and its 
ligands in the human hepatocarcinoma cell line, HepG2. We found that several 
environmental pollutants (AhR ligands) induce SOS1 gene expression by increasing its 
transcription. Chromatin Immunoprecipitation experiments demonstrated that the AhR 
binds directly and activates the SOS1 gene promoter. We also showed that dioxin 
treatment leads to an activated Ras-GTP state, to ERK activation and to accelerated 
cellular proliferation. All these effects were mediated by SOS1 induction as shown by 
knock down experiments. Our data indicate that dioxin-induced cellular proliferation is 
mediated, at least partially, by SOS1 induction. Remarkably, our studies also suggest 
that SOS1 induction leads to functional effects similar to those elicited by the well-
characterized oncogenic Ras mutations.  
  
 
 
 
 
 
Keywords : Dioxin, AhR, SOS1, Ras, Cell proliferation 
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1. Introduction 
The Ras signalling pathway is involved in cell growth and differentiation. Mutations 
in the Ras proto-oncogene have been described in a large variety of human malignancies [1]. 
These mutations result in a constitutively active Ras protein, which is one of the most 
common Ras dysregulations in cancers [1, 2]. Three different Ras genes encoding the H-Ras, 
K-Ras and N-Ras 21 kDa proteins were discovered 30 years ago [1, 3]. The activated Ras 
proteins physically associate with and activate Raf-1, a serine/threonine kinase which triggers 
a kinase cascade that results in the activation of the extracellular signal-regulated protein 
kinases (ERKs of the MAPK family). Ras acts as a functional hub by activating multiple 
downstream pathways that participate in cell growth and differentiation. The activity of Ras is 
regulated by two sets of proteins: guanine-nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs). GEFs stimulate the release of the Ras bound GDP which then 
allows GTP to bind and activate Ras. Conversely, GAPs stimulate Ras GTPase activity and 
lead to the basal GDP-bound state.  
Several pathways, which lead to the active Ras state, have been described in 
mammalian cells. The best-characterized pathway employs the activation of tyrosine kinase 
receptors to elicit binding of various proteins to the phosphorylated receptor, most notably the 
growth factor receptor bound 2 (Grb2) protein bound to the guanine nucleotide exchange 
factor SOS1. The complex is targeted to the plasma membrane, allowing the GEF function of 
SOS1 to activate Ras by GDP/GTP exchange [4-6]. SOS1 can activate other GTP-binding 
proteins [4] and other effectors also control Ras activity. The most extensively characterized 
non-physiological conditions under which increased SOS activitiy has been observed result 
from gain of function mutations. For example, SOS1 mutations have been described in the 
Noonan syndrome, a developmental disorder that is characterized by short stature, facial 
dysmorphia, congenital heart defects and skeletal anomalies [7, 8]. These gain of function 
mutations, which lead to the activation of Ras and were the first examples of activating GEF 
mutations associated with human disease. Surprisingly, the implications of increased 
expression of SOS proteins have not been addressed and little is known about the regulation 
of the gene promoter.  
Dioxin is a member of the PolyChlorinated dibenzo Dioxins (PCDD) family which is 
a class of highly persistent environmental contaminants. 2,3,7,8-TetraChloroDibenzoDioxin 
(TCDD), the most extensively characterized dioxin, has been classified in 1997 as a “human 
carcinogen” by the International Agency for Research on Cancer (IARC) [9]. This pollutant is 
the ligand with the greatest affinity for the Aryl Hydrocarbon Receptor (AhR). TCDD via the 
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AhR, induces various toxicities including chloracne, wasting syndrome, teratogenicity, 
immunotoxicity, neurotoxicity, tumor promotion and carcinogenesis [10]. The AhR is a 
cytosolic, ligand-activated transcription factor which, upon activation, translocates to the 
nucleus where it forms a heterodimer complex with AhR Nuclear Translocator (ARNT). This 
complex binds to specific Xenobiotic Responsive Elements (XRE) which are characterized by 
a 5’-GCGTG-3’ consensus core and induces specific target genes which include xenobiotic 
metabolizing enzymes (XME) such as the cytochrome P450 (CYP) 1 family [11]. In addition 
to detoxification functions, the activation of this receptor has been shown to elicit diverse 
cellular effects including cell proliferation [12, 13]. These cellular alterations might mediate 
part of the long-term toxicity of the AhR ligands in animals and humans [14]. Indeed, AhR-
null mice display several defects of development and proliferation including thymus and liver 
hypotrophy [15]. Numerous studies using AhR defective cells or AhR invalidating strategies 
have clearly established a role for this receptor in cell cycle regulation and proliferation [16]. 
The dysregulation of these cellular pathways may disrupt normal fetal development and favor 
cancer progression. The AhR gene targets that are involved in the proliferative effects of this 
receptor are not completely identified. To this end, we have examined large-scale 
toxicogenomic analyses of dioxin effects and focused on regulatory proteins that control 
cellular growth, in particular, the main mediator of Ras activation, SOS1.  
In the present work, we investigated, for the first time, the regulation of the previously 
uncharacterized SOS1 gene promoter by the AhR and its ligands in the human 
hepatocarcinoma cell line, HepG2. We show that several environmental pollutants (AhR 
ligands) induce SOS1 gene expression via increased transcription. Moreover, considering the 
critical role of SOS1 in controlling Ras activity, we also demonstrate that induction of SOS1 
by AhR ligands leads to a predominant Ras-GTP state, to MAPK activation and to cell 
growth. The results point towards SOS1 gene induction as being a critical step for the 
carcinogenic effects mediated by dioxins. 
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2. Materials and methods 
2.1. Cell Culture. Human hepatocarcinoma HepG2 cells were cultured
 
in Dulbecco's 
minimal essential medium (DMEM, Invitrogen, Cergy-Pontoise, France) supplemented
 
with 
nonessential amino acids and containing 10% fetal bovine serum, 200 U/mL penicillin, 50 
µg/mL
 
streptomycin (Invitrogen) and 0.5 U/mL amphotericin B (Bristol-Myers Squibb Co., 
Stamford, CT) at 37°C in a
 
humidified atmosphere of 5% CO2 in air. The day before with the 
addition of various concentrations of TCDD, cells were cultured in DMEM without phenol 
red and supplemented with 3% charcoal-treated (desteroidized) calf serum. Cells were 
maintained in this medium during all the treatments except for the proliferation studies. 
TCDD was purchased from LCG Promochem (Molsheim,
 
France).  Benzo(a)pyrene, and 
quercetin were purchased from Sigma-Aldrich (St Louis, United States). 
2.2. RNA extraction, reverse transcription and quantitative RT-PCR. Total RNAs 
were extracted using the RNeasy mini kit (Qiagen, Les Ulis France) and reverse transcription 
was performed with
 
each RNA sample using the cDNA High-Capacity Archive
 
kit (Applied 
Biosystems, Courtaboeuf, France) as previously described [17]  . Specific oligonucleotides 
were designed using
 
the OLIGO Explorer software (Molecular Biology Insights, Inc.,
 
Cascade, CO). Gene specific primers used for the real time PCR were: SOS1: forward 5’-
TGAGAGGCAACAGAAAGAGC-3’ and reverse 5’-GAGAAGGGAAATGAAATGGG-3’; 
AhR: forward 5’-ACATCACCTACGCCAGTCGC-3’ and reverse 5’-
TCTATGCCGCTTGGAAGGAT-3’; RPL13A:  forward 5’-
CCTGGAGGAGAAGAGGAAAGAGA-3’ and reverse 5’-
GAGGACCTCTGTGTATTTGTCAA-3’. Oligonucleotides were obtained from (Qiagen). 
Quantitative RT-PCR was carried out in a 10 µL reaction volume containing 40 ng of cDNA, 
300
 
nM of each primer and ABsolute™ QPCR SYBR® Green (Abgene, Villebon sur Yvette, 
France). Quantitative
 
RT-PCR measurements were performed on an ABI Prism 7900 
Sequence
 
Detector system (Applied Biosystems). PCR cycles consisted of the following 
steps: Taq activation (15 min, 95°C), denaturation (15 s, 95°C)
 
and annealing and extension 
(1 min, 60°C). The threshold
 
cycle (Ct), which is inversely correlated to the amount of target 
mRNA,
 
was measured as the number of cycles for which the reporter fluorescent emission 
first exceeds the background. The relative amounts of mRNA were estimated using the ΔΔCt 
method with RPL13A as reference.  
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2.3. Immunoblotting. Whole cell lysates were prepared as previously described [17] 
from HepG2 cells with M-PER®, Mammalian Protein Extraction Reagent, containing 
protease and phosphatase inhibitor cocktails (Sigma-Aldrich, St Louis, United States). Equal 
amounts of total protein were separated by SDS–PAGE and transferred onto nitrocellulose 
membranes (GE Healthcare, Orsay, France). The membranes were probed with primary 
antibodies recognizing SOS1 (Upstate, Molsheim, france, 07-337, 1:2000), Actin (Abcam, 
Paris, France ab37063, 1:10000), AhR (Abcam, ab2770, 1:1000), ERK-Phosphorylated (Cell 
signaling, Saint Quentin en Yvelines, France 9101, 1:2000), ERK (Cell signaling, 4695, 
1:2000) and Ras (Upstate 05-516, 1:10000). Immunoreactive bands were detected with X-ray 
film using alkaline phosphatase-linked secondary antibody (Applied biosystems, T2191 or 
T2192, 1:20000) and an enhanced chemiluminescence system CDP-Star® (Applied 
biosystems). Relative Quantification of the amount of immunreactive material was performed 
with ImageJ freeware (http://rsb.info.nih.gov/ij/). 
 
2.4. SOS1 mRNA half-life measurement. On day 1, HepG2 cells were seeded at 400 
000 cells/well (in 6-well plates) in complete DMEM medium (see above). On day 2, cells 
were washed with PBS and the medium was replaced by red phenol-free DMEM 
supplemented with 3% desteroidized fetal bovine serum, 200 U/mL penicillin, 50 µg/mL
 
streptomycin and 0.5 mg/mL amphotericin B. Then TCDD dissolved in medium (1µM). Fifty 
µL was added to the cells medium to give a final concentration of 25 nM. Twenty four hours 
later (on Day 3), cells were treated with 100µM DRB (5,6-dichloro-beta-D ribofuranosyl 
benzimidazole, Sigma-Aldrich) and lysates were extracted at 0, 2, 4, 6, 10 and 12 hours after 
the addition of DRB using the RNeasy mini kit (Qiagen)  Quantitative real-time PCR was 
then performed. 
 
2.5. In silico analysis and primer extension. In silico analysis was performed with 
MatInspector
®
 software (Genomatix, Munich, Germany) to identify all the potential 
consensus responsive elements in the promoter. For the primer extension study, total RNAs 
were extracted using the RNeasy mini kit (Qiagen) as described. Primer extension 
experiments were performed with the Primer Extension System-AMV Reverse Transcriptase 
kit (E3030, Promega, Charbonnières les Bains, France). Positive and negative controls are 
provided with the Kit from Promega. A specific primer was designed (+100 5’-
GGGACCCCGCTTCCCGGCCGCAGC-3’ +123) (+ 1 refers to translation start site) and 
labeled with [γ32P]ATP (Easytides, BLU502A001MC, Perkin-Elmer, Courtaboeuf, France). 
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The reverse transcription product was separated on a denaturing acrylamide gel. After 
migration, radioactive bands were visualized with a phosphorimager (STORM 580). 
2.6. siRNA transfection. The day before the transfection, HepG2 cells (4 x 10
5
 cells / 
well) were seeded in
 
6-well plates. The medium was replaced the day of the transfection by 
DMEM , without phenol red, supplemented with 3% charcoal-treated (desteroidized) calf 
serum. Cells were then transfected with 20 nM SOS1 siRNA, using the Lipofectamine 2000 
transfection reagent (Invitrogen) according to the manufacturer's protocol and with 5 nM AhR 
siRNA using the HiPerfect transfection reagent (Qiagen) according to the manufacturer's 
protocol. For SOS1 and AhR experiments, the medium was replaced after 24 h of incubation 
at
 
37 °C and cells were treated or not with 25nM TCDD. RNA and protein purification were 
carried out 48 h after the transfection. siRNA references and/or sequences (Qiagen) were:  
 siSOS1: Hs_SOS1_5_HP Validated siRNA (ref : SI02655121) 
 siAhR: Hs_AHR_5_HP Validated siRNA (ref: SI02780148) 
 siControl: GFP Custom siRNA (ref: 1027020) 
2.7. Reporter assays. pGLuc basic vector (New England Biolabs, Ipswich, MA) was 
digested with BglII and HindIII restriction enzymes (New England Biolabs). For the 
construction of the SOS1 promoter (AF 106953) the-2200,+37 region;(+ 1 refers to the 
translation start site) was amplified using the following primers : -2200 5’-
CTTAGATCTAAGTGGGGAGTTTTTCAAATGT-3’ -2170 and +37 5’-
AAGCTTTCGCTGAAAAACTCGTAGGG-3’ +17. The PCR product was cut with the same 
restriction enzymes. Transfection experiments were performed as described in siRNA 
transfection paragraph, using 1µg of plasmid. The empty pGLuc basic vector (New England 
biolabs) was used as transfection control. Twenty-four hours after the transfection, 50 µL 
supernatant (containing the secreted luciferase) were collected and the medium was changed. 
The cells were then treated or not with 25 nM TCDD as described above. The supernatant 
was then harvested at0h, 6h, 24h and 48h after TCDD treatment. A luciferase assay (Gaussia)
 
was performed with a New England Biolabs kit (E3300L) and a luminometer (Lumat 
LB9507, Berthold, Thoiry, France). 
2.8. Chromatin Immunoprecipitation. HepG2 cells were seeded into 150-mm-diameter 
dishes (approximately 20x10
6
 cells per dish) 48h before being processed for ChIP as 
previously described [17]. Treatment with TCDD (25nM) was performed, as described above, 
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for 15- and for 45 min. We used a ChIP-grade antibody from BioMol (anti-AhR antibody, Cat 
SA-210, BioMol, Plymouth Meeting, Pennsylvania, USA)  ChIP DNA was analysed by 
quantitative PCR using the specific primers covering the region between – 984 bp and – 801 
bp of the human Sos1 promoter region (forward primer: 5’-GGTTTCGTGACAGAGCACCT-
3’ and reverse primer 5’-TAAAGAGGCTCCCCATTGTG 3’) and non-specific primers 
(forward primer: 5’-TGGGGTAGACTGTGGCAGA-3’ and reverse primer 5’-
GGCTAAGGATTCAGCAGCAA-3’). 
2.9. Ras activity. On day 1, cells were seeded at approximately 15 million cells per 
175-cm2 plate. Twenty-four hours later (day 2), the medium was changed and siRNA SOS1 
transfection was performed (see above). On Day 3, the medium was changed and TCDD 
(25nM) was added as previously described. On day 4, the medium was replaced with a 
medium without serum containing or not TCCD (25nM). On day 5, cells were lysed in 
Magnesium Lysis Buffer (MLB, Upstate) containing protease and phosphatase inhibitor 
cocktails (Sigma). Equal amounts of total protein extracts, treated or not, were incubated with 
Raf-RBD GST beads (Cytoskeleton, Le Perray en Yvelines, France RF-02A), to retain only 
the active form of Ras, (Ras-GTP) following the manufacturer’s recommendations (Upsate). 
The recovered proteins were separated by SDS–PAGE (see above) and western blots (Ras 
antibody) were performed. Moreover, we used GTP gamma-S as a positive control and GDP 
as a negative control  (Upstate). 
 
2.10. Cell growth.  On day 1, cells were seeded at 30,000 cells / well (in 6-well plates) 
in complete DMEM medium (see above). On day 4, siRNA SOS1 and siRNA AhR 
transfection was performed (see above). On day 5, cells were treated with TCDD (25nM) as 
above. For each condition, the number of cells per well was counted at times corresponding to 
0h, 24h and 48h of TCDD treatment. For cell counting, cells in each well were trypsinised 
with 150 µL of Trypsine-Versene (Invitrogen), which was neutralized, with 150 µL of 
complete medium. 
 
2.11. Statistical analysis. The data result from at least three independent experiments. 
The results were expressed as the mean ± standard error. Differences between groups were 
analyzed by U Mann-Whitney’s test (nonparametric comparison of 2 independent series) or H 
Kruskal-Wallis’s test (nonparametric comparison of k independent series) followed by a 1-
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factor ANOVA test (parametric comparison of k independent series). A p-value < 0.05 was 
considered as statistically significant. 
 
3. Results  
 
TCDD is known to promote cellular proliferation and cell cycle progression in 
different cellular models. Since several toxicogenomic large-scale studies, including our own, 
were performed in the human hepatocarcinoma HepG2 cell line and since this cell line 
exhibits high levels of AhR expression, we used the HepG2 cells for our gene regulation 
studies. As will be shown later in this article, TCDD elicited a 20% increase in the number of 
cells during the exponential phase of growth. Thus, the HepG2 cells constitute an appropriate 
model to investigate the molecular mechanisms of TCDD-elicited cellular proliferation. 
 
3.1. Effect of dioxin treatment on SOS1 mRNA and protein levels in HepG2 cells. In 
a large-scale gene expression study, SOS1 mRNA was found to be induced by TCDD [18]. 
First, we validated those observations in HepG2 cells. We performed kinetic and dose-
response experiments and we extracted both total RNA and total protein. SOS1 expression 
was assessed using both quantitative real-time PCR (Figures 1A & C) and immunoblotting 
(western blots) (Figures 1B & D). Dose-response experiments showed that TCDD up-
regulated SOS1 mRNA expression (Figure 1A) and protein level (Figure 1B and 
supplementary figure 1A). The response was significant for concentrations higher than 10 nM 
TCDD. Consequently, 25nM TCDD was used in the following experiments. This 
concentration of TCDD is within the usual concentration range used to treat human cells (5-
100 nM). Figures 1C-D and supplementary figure 1B show that SOS1 was significantly up-
regulated by 25 nM TCDD in a time-dependent manner. In addition to HepG2 cells, we have 
also observed a significant up-regulation of SOS1 mRNA in several mouse tissues (C57/Bl6) 
following TCDD treatment (Supplementary figure 2). These results indicate that SOS1 is up-
regulated upon TCDD treatment and suggest that the SOS1 gene might be an AhR 
transcriptional target.  
 
3.2. SOS1 mRNA and protein induction is AhR-dependent. We examined the 
contribution of the Ah Receptor using different AhR ligands including TCDD, 
Benzo(a)pyrene and quercetin (Figure 2A) and a RNA interference knock down strategy 
(Figures 2B, 2C & 2D). Figures 2A shows that the AhR ligands, 25 nM TCDD and 5 µM 
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BaP, significantly increased SOS1 mRNA; although an increase in SOS1 mRNA was also 
observed after treatment of cells with 25 µM Quercetin, this increase was not significant. We 
then knocked down AhR expression using specific siRNA (Fig 2B), which decreased AhR 
mRNA by approximately 60-70% (Fig 2B). AhR levels remain knock-downed throughout the 
time course of the experiment (Supplementary figure 3). Figure 2C and 2D show that AhR 
siRNA treatment elicited a statistically significant 50% decrease in both SOS1 mRNA and 
protein induction by TCDD. In this experiment, we did not expect to completely knock-down 
AhR levels but we aimed to correlate the relationship between both AhR and SOS1 levels; we 
observed such a correlation (AhR by the time of treatment, 0h, 50% decreased levels and 
SOS1 at the end of the experiment, 50% decrease) and also a 60% decrease in CYP1A1 
induction which is classically measured to prove AhR activation (data not shown). These 
experiments demonstrate that the activated AhR regulates SOS1 mRNA and protein levels. 
 
3.3. The SOS1 gene promoter is a direct target of the AhR. To further characterize 
the mechanism of SOS1 induction by TCDD, we blocked RNA polymerase II with DRB and 
measured SOS1 mRNA levels upon TCDD treatment, as well as under untreated conditions. 
Figure 3 shows that the rate of SOS1 mRNA decline was not significantly different in treated 
and untreated conditions suggesting that a decreased rate of SOS1 mRNA degradation is not 
involved in the TCDD up-regulation of SOS1 mRNA (Figure 3A). Very recently, the exon-
intron structure of the SOS1 gene was displayed in the Pubmed Ace View Database. Exon 1 
is shown to start 280 bases upstream of the translation start site for the longest variant. Other 
mRNA variants differing in the length of the 5' ends have been found in different tissues but 
little information was given on their abundance. To further define the length of the 5' UTR in 
our cell line model, we performed a primer extension study, which confirmed the presence of 
a major start site approximately 150 bp upstream from the translation start site, which is in 
line with the displayed gene structure (data not shown). A minor transcription start site was 
also observed downstream from the major one, which is not surprising in this GC-rich 
promoter. Then we performed a MatInspector
®
 analysis of the 2200 base pairs located 
upstream of the transcription start sites to identify consensus AhR sequences (Xenobiotic 
Responsive Elements or XRE); Figure 3B shows the positions and the sequences of 2 putative 
XREs (AhR binding).  
Several experiments were carried out in order to determine whether the SOS1 gene 
promoter is a direct target of the AhR, including luciferase reporter gene assays (Figure 4A 
and 4B) and Chromatin ImmunoPrecipitation (ChIP) assays using a specific AhR antibody 
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(Figure 4C). We subcloned the (-2200/+37) fragment of the SOS1 gene promoter (which 
includes the two putative XREs) upstream of the Gaussia luciferase reporter gene. The 
activity of this gene product can be readily monitored in the medium. Following transfection 
with this recombinant reporter gene plasmid, HepG2 cells were treated with TCDD and the 
medium was recovered at different time points for luciferase assay (Figure 4A). A significant 
increase in luciferase activity can be observed 24 and 48 hours following TCDD treatment. 
These experiments confirm that the (-2200/+37) SOS1 gene fragment exhibits promoter 
activity as compared to the empty vector (Figure 4B), and suggest that this gene promoter 
fragment mediates part of the inducing effect of TCDD. Similar experiments were performed 
in control siRNA and AhR-siRNA treated cells (Fig 4B). We observed a similar 2- to 3-fold 
increase in the activity of the SOS1 gene promoter in siControl-transfected cells upon TCDD 
treatment. However, basal and induced SOS1 promoter activities were significantly reduced 
in AhR-depleted cells suggesting a contribution of this receptor to SOS1 gene promoter 
activation.  
Finally, we performed a Chromatin Immuno Precipitation (ChIP) experiment using a 
SOS1 promoter fragment (-984/-801) to confirm the direct binding of AhR to the endogenous 
SOS1 gene promoter (Figure 4C). AhR antibody and real-time PCR were used to provide a 
quantitative measurement of receptor binding. Cells were treated for 15 and 45 minutes with 
TCDD. Several controls were used for the experiments (inputs, mock antibody). We observed 
a time-dependent, specific and potent increase of AhR binding to the SOS1 gene promoter. 
Altogether, these experiments clearly show that the TCDD-mediated transcriptional 
regulation of the SOS1 gene is related to the rapid direct binding of the AhR to the promoter.  
 
3.4. TCDD stimulates Ras activity and ERK1/2 phosphorylation through induction 
of SOS1. Since the Guanine nucleotide Exchange Factor SOS1 regulates the Ras-MAPK 
pathway, we hypothesized that increased amounts of SOS1 could lead to the activation of this 
pathway. Thus, we monitored Ras activity (the active GTP-bound form) and ERK 
phosphorylation following TCDD treatment of HepG2 cells. To monitor Ras activity, we 
performed affinity pull-down experiments. Beads grafted with the domain of Raf, which 
specifically interacts, with the GTP-bound form of Ras were mixed with different cellular 
extracts. The bound fraction was then eluted and analyzed with a Ras antibody. Figure 5A 
shows that the active form of Ras was increased following TCDD treatment. In parallel, the 
phosphorylated fraction of ERK was also increased by TCDD treatment (fig 5B). To assess 
the implication of SOS1 in these processes, we down-regulated SOS1 expression using a 
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specific siRNA and observed a clear decrease of TCDD-induced Ras-GTP levels as shown in 
figure 5C. SOS1 protein levels remain knocked down throughout the time course of the 
experiment. These results show that SOS1 is a critical mediator of TCDD-dependent RAS-
MAPK pathway activation. Importantly, for the first time, these observations show that 
increased amounts of SOS1 are sufficient to activate the downstream pathway indicating that, 
in HepG2 cells, the amount of SOS1 is limiting. It is noteworthy, however, that the Ras 
pathway activation by TCDD is delayed as compared to the time course of the response which 
can be traditionally achieved by Tyrosine Kinase receptor activation [19]. 
 
 3.5. SOS1 and AhR are critical for dioxin-dependent changes in growth. Since the 
Ras-ERK pathway in implicated in cell growth, we tested the effect of TCDD treatment on 
HepG2 cells proliferation. As shown in figure 6A & 6B, TCDD elicited a statistically 
significant 20% increase in cellular growth in the absence or in the presence of a control 
siRNA. Following the knock down of SOS1 gene expression (Fig 6A) using two specific 
siRNAs, the effect of TCDD was completely abolished. A partial decrease in basal cellular 
proliferation was also noted, which is not surprising given the implication of the SOS1-Ras-
ERK pathway in cellular proliferation. In addition, AhR-specific siRNAs also prevented the 
TCDD effects (Fig 6B). We conclude that SOS1 induction plays a critical role in the TCDD-
elicited increase in cellular proliferation.  
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4. Discussion 
 
AhR activation by polyaromatic and polyhalogenated hydrocarbons has traditionally 
been associated with induced expression of phase I and phase II xenobiotic metabolizing 
enzymes, which promote the clearance of pollutants and drugs from metazoan organisms [20]. 
However, recent toxicogenomic studies, as well as knock-out studies in mice, have unveiled 
new AhR target genes [13, 21-23] and suggested novel functions for this receptor including 
the regulation of cell proliferation and migration. Several large-scale studies in HepG2 cells 
[21, 22, 24] indicated that the SOS1 gene could be a target of TCDD. SOS1, a Guanine 
Exchange Factor, is essential for the activation of the Ras and Rac signaling pathways, which 
lead to the regulation of some of the most important cellular functions including cell division, 
differentiation and migration [4]. Despite these critical roles, neither the regulation of SOS1 
expression nor the characterization of its gene promoter has been carried out previously. We 
recently observed that AhR ligands increase HepG2 cell proliferation and hypothesized that 
increased SOS1 expression might be involved in this biological effect. We first validated our 
transcriptomic experiments and showed that the AhR and its ligands positively regulate SOS1 
gene expression. Then, we characterized and subcloned, for the first time to our knowledge, 
the human SOS1 gene promoter. We showed that TCDD and other AhR ligands regulate, via 
transcriptional mechanisms their activities upon AhR activation followed by direct promoter 
binding of AhR to XRE sites. Interestingly, the level of induction of SOS1 elicited by each 
ligand is different. This is in line with one of our former studies showing that the 
transcriptional response of the AhR depends on the nature of its ligand ([25]) and, more 
generally, with the SAhRM concept [26]. Finally, we focused on the implications of the 
regulation of SOS1 expression by environmental pollutants. Using a siRNA strategy, we 
demonstrated that increased SOS1 expression is directly linked to Ras and ERK activation, 
which promotes cell division. This study demonstrates that the activation of the Ras-ERK 
pathway could be achieved by increasing the amount of the SOS1 protein. These results 
suggest that, under our cell culture conditions, the amount of SOS1 protein is limiting.  
 
The activation of the Ras ERK pathway has been studied extensively in the past and 
several mechanisms have been reported and characterized [19]. Receptor activation followed 
by SOS1 recruitment is a classical mechanism under physiological and certain pathological 
conditions and is one paradigm for cellular signaling [6]. In cancer cells, considerable 
research has been devoted to the upregulation of this pathway through activating Ras 
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mutations. Similarly, the function of SOS1 has been considerably investigated [27-29]. 
Recent studies also have correlated SOS1 activating mutations to several diseases of 
development including Noonan syndrome, a developmental disorder characterized by short 
stature, facial dysmorphia, congenital heart defects and skeletal abnormalities [7, 8, 30] as 
well as hereditary gingival fibromatosis type 1, a benign overgrowth condition of the gingiva 
[31]. Despite considerable attention to these gains of function mutations, SOS1 gene 
regulation has remained poorly characterized [32, 33]. We speculate that the findings reported 
here on the upregulation of SOS1 gene expression by environmental pollutants might 
constitute one mechanism, which accounts for TCDD and other AhR ligand-mediated 
carcinogenesis. We expect this effect to be particularly relevant in cancerous cells, which do 
not exhibit Ras mutations. Indeed, continuous upregulation of SOS1 in these cells may mimic 
Ras mutational activation and lead to the permanent stimulation of the downstream signaling 
pathway, which controls cellular proliferation. Thus, our data imply that increased SOS1 
expression may constitute an alternative to the activating mutations of Ras and that it should 
be relevant to explore and characterize alterations of the expression of this gene in cancer 
cells [34-36]. Furthermore, it is unclear at this stage whether these two mechanisms can be 
additive or not. An important question, in this respect, is whether gene induction-mediated 
chronic activation of the SOS1/Ras pathway can be achieved readily in humans. Because of 
the high contamination levels and widespread distribution of AhR ligands in our environment, 
chronic exposure to such pollutants is very common, especially in industrialized countries. In 
addition, long term effects could also be triggered by acute high level exposure to these 
toxins. Indeed, pollutants such as dioxins tend to resist metabolism and accumulate in human 
and animal adipose tissue, leading to a permanent internal exposure [37].  
 
Genetic and developmental studies in flies and mice have suggested different and unexpected 
connections between the AhR and the small G proteins network. A recent study by Carvajal-
Gonzalez JM et al using AhR KO mice models, has unveiled a link between the receptor and 
the Vav3, a guanosine diphosphate/guanosine triphosphate exchange factor for Rho/Rac 
GTPases [38]. Moreover, Son of Sevenless (SOS) has been shown to be a major player in the 
development of Drosophila eye ommatidia. SOS mutations change ommatidia organization 
and the color perception of the fly [39, 40]. Spineless, the Drosophila AhR ortholog, is 
involved in the ommatidal mosaic formation as well as SOS1 [41]. Thus, these two genes 
converge in the control of eye development. It is tempting to speculate that this genetic 
interaction may be related to a possible conservation of the control of SOS gene expression by 
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spineless in this invertebrate species. Interestingly, invertebrate AhR orthologs (Spineless and 
AHR-1 from Caenorhabditis elegans) display structural and functional similarities with 
vertebrate AhR such as transcription factor activity and XRE binding. However, they do not 
bind dioxins or other hydrocarbon ligands and, at this stage, their possible receptor functions 
and their activation mechanisms have not been characterized. It is intriguing to consider that, 
while Spineless and AHR-1 are implicated in fundamental developmental processes, recent in 
vivo and in vitro evidences have established direct connections between the mammalian AhR 
and developmentally relevant pathways such as cellular proliferation, cellular migration and 
epithelial mesenchymal transition [42, 43]. Thus, it is likely that several of those AhR 
functions including SOS1 regulation, have been conserved through evolution and the present 
study as well as several others suggest that one mechanism of pollutants toxicity would be to 
disrupt such basic developmental functions of this receptor.  
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6. Legends for figures 
 
Figure 1: SOS1 is a target of TCDD in human hepatocarcinoma HepG2 cells. (A) 
Quantitative real-time PCR (A, C) and western blot analysis (B, D) of SOS1 mRNA and 
protein levels as a function of TCDD concentration (0-100 nM, 48h) (A, B) and as a function 
of time (0-48h, 25 nM TCDD) (C, D) in human hepatocarcinoma HepG2 cells. Relative 
mRNA levels were calculated using controls values (0 nM for A or 0h for C) as references. 
Actin was used as a loading control for western blots. **, p < 0.01 as compared to non-treated 
controls (n > 3). 
 
Figure 2: Involvement of the AhR in the regulation of SOS1 mRNA and protein 
expression in HepG2 cells. (A) SOS1 mRNA levels measured by quantitative real-time PCR 
after 48h-treatment of HepG2 cells with various AhR ligands (TCDD, 25 nM; 
Benzo(a)pyrene or BaP, 5 µM; Quercetin, 25 µM). Relative mRNA levels were calculated 
using control value as reference (B) AhR mRNA levels measured by quantitative real-time 
PCR in AhR (siAhR) or control (siC) siRNA-transfected HepG2 cells (NT: non-treated; 
TCDD: TCDD-treated). (C) SOS1 mRNA levels measured by quantitative real-time PCR in 
AhR (siAhR) or control (siC) siRNA-transfected HepG2 cells (NT: non-treated; TCDD: 
TCDD-treated). (A, B, C: ***, p < 0.001; **, p < 0.01 and *, p < 0.05 compared to controls 
(n>3)). (D) Western blot analysis and relative quantification of SOS1 and AhR protein levels 
in AhR (siAhR) or Control (siC) siRNA-transfected HepG2 cells upon TCDD (+) treatment. 
Actin was used as a loading control for western blots (n=3).  
 
Figure 3: The AhR dependent-SOS1 regulation is transcriptional. (A) SOS1 mRNA 
levels measured by relative quantitative real-time PCR in the presence of DRB, an inhibitor of 
RNA polymerase II in non-treated (NT + DRB) and TCDD-treated (T + DRB) HepG2 cells. 
Cells were treated or not with 25 nM TCDD for 16h then with DRB and subsequently 
harvested (between 0 and 12h). We use a semi-logarithmic representation. (B) Diagram of the 
SOS1 promoter (-2200/+37) using the translation start site as reference (+1).  Localizations of 
both XRE consensus sites (-940 and -2060 bp) and oligonucleotides used for primer extension 
assay, ChIP and EMSA are indicated as well as the promoter section used for the reported 
gene (luciferase) experiments (see below). 
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Figure 4: SOS1 regulation depends on the binding of the AhR to SOS1 promoter. (A) 
Diagram of the SOS1 promoter subcloned in the Gaussia luciferase basic vector (with both 
XRE consensus sites at -940 and -2060 bp) and activity of the SOS1 promoter measured after 
transfection of HepG2 cells with a vector (pGLuc-SOS1) containing the -2200/+37 theoretical 
promoter region of SOS1 upstream from the Gaussia luciferase reporter gene (+1 refers to the 
translation start site). The cells were treated (+) or not (-) with TCDD. The medium was 
sampled after 0, 6, 24 and 48 hours. An empty vector (pGLuc) was used as a control. Relative 
luciferase activities are reported on the y-axis and are calculated using non-treated conditions 
(-) as control reference for both vectors (B) Activity of the SOS1 promoter measured after 
transfection of HepG2 cells with a control (siC) or AhR targeting (siAhR) siRNA and the 
vector containing the -2200/+37 theoretical promoter region of SOS1 upstream from the 
Gaussia luciferase reporter gene (pGLuc-SOS1). The cells were treated (+) or not (-) with 
TCDD for 48h. The medium was sampled after 48 hours. An empty vector (pGLuc) was used 
as a control. Relative luciferase units (RLU) are reported on the y-axis (C) Electrophoretic 
Mobility Shift Assay (EMSA) using a specific labeled double strand probe encompassing the 
first XRE site in the SOS1 gene promoter (-940, see figure 3 and 4A), nuclear HepG2 extracts 
(cells were treated or not with 25 nM TCDD for 75 mins), an unlabelled competitive 
oligonucleotide (compet. XRE1 SOS1 with the same sequence than the probe, 10X and 20X) 
an AhR antibody (anti-AhR, 3 and 6 µg) and an unlabelled competitive oligonucleotide 
(compet. XRE1 SOS1 with a mutated sequence 20X) (D) Chromatin Immunoprecipitation 
(ChIP) performed with a mock or a specific AhR antibody (15 or 45 minutes of TCDD 
treatment of HepG2 cells, respectively T15 or T45). Specific primers surrounding the 
proximal XRE (-940, see figure 3 and 4A) of the Sos1 gene promoter were used for the study. 
Input refers to non-precipitated samples and is used to ensure proper “loading” controls 
before precipitation. The mock antibody is used to measure unspecific precipitations. Fold 
induction refers to relative levels calculated using non-treated (NT) conditions as reference. 
***, p < 0.001 and *, p < 0.05 as compared to controls (n=3). 
 
Figure 5: Increased expression of SOS1 after TCDD treatment stimulates Ras activity 
and ERK1/2 phosphorylation (A) Western blot analysis of Ras-GTP protein levels after a 
Ras-GTP specific pull down assay in untreated (-) or 25 nM TCDD-treated (+) HepG2 cells 
upon 48h treatment. Input Ras levels show the levels of Ras before precipitation. Precipitation 
is undertaken using a protein, which specifically interacts with Ras-GTP (Raf), linked to 
GST-beads. Negative (Ctrl -) and positive (Ctrl +) control respectively refers to extracts over-
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treated with GDP or GTP-S before precipitation (see Material and methods for more details) 
(B) Western blot analysis of phosphorylated ERK levels (ERK-P) in untreated (NT) or 
TCDD-treated (T) HepG2 cells. Total ERK was used as a loading control. The quantification 
of three independent experiments is presented in the right panel. Fold induction refers to 
relative levels calculated using the NT condition as reference.  *,p < 0.05 compared to 
controls (n=3). (C) Western blot analysis of Ras-GTP and SOS1 protein levels after Ras-GTP 
specific pull down assays of untreated (-, NT) or 25 nM TCDD-treated (+, T) HepG2 cells 
extracts after SOS1 (siSOS1) or control siRNA (siC) transfection. The quantification of three 
independent experiments is presented in the right panel for both SOS1 and Ras-GTP proteins. 
Fold induction refers to relative levels calculated using NT conditions as reference. ***, p < 
0.001 and **,p < 0.01 compared to controls (n=3). 
 
Figure 6: TCDD-stimulated HepG2 cell growth depends on both AhR expression and 
increased expression of SOS1. (A) HepG2 cells were either not transfected (wo si RNA) or 
transfected with control siRNA (siC) or SOS1 siRNA (siSOS1). One day after, they were 
treated (T) or not (NT) with 25 nM TCDD for 24 h. Cell numbers, expressed in AU (Arbitrary 
Unit), were quantified for each condition. In the right panel of the figure, a western blot-
analysis of SOS1 protein levels is presented. (B) HepG2 cells were either not transfected (wo 
si RNA) or transfected with siControl (siC) or siAhR (siAhR). They were treated (T) or not 
(NT) with 25 nM TCDD for 48 h. Cell numbers, expressed in AU (Arbitrary Unit), were 
quantified for each condition. In the right panel of the figure, a western blot-analysis of AhR 
protein levels is presented *,p < 0.05 compared to controls (n=3). 
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